Xeomin (incobotulinumtoxinA) is a prescription neurotoxin manufactured by Merz Pharmaceuticals that temporarily reduces muscle activity by blocking acetylcholine release at the neuromuscular junction. It is FDA-approved for both therapeutic indications (cervical dystonia, blepharospasm, chronic sialorrhea, upper limb spasticity) and cosmetic use on the upper face.
In July 2024, the FDA expanded Xeomin's cosmetic approval to include forehead lines and lateral canthal lines (crow's feet) in addition to its existing glabellar lines indication. This made Xeomin the first and only neurotoxin approved for the simultaneous treatment of all three upper facial treatment areas.
This article covers what Xeomin is, how it differs from other neuromodulators, what the evidence supports, who it suits best, what it costs, and what the real risks are.
What Xeomin is and how it works
Xeomin contains botulinum toxin type A, the same active molecule found in Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Daxxify (daxibotulinumtoxinA-lanm), Jeuveau (prabotulinumtoxinA-xvfs), and Letybo (letibotulinumtoxinA). All of these products work by the same mechanism: they cleave SNAP-25, a protein required for acetylcholine vesicle fusion at the neuromuscular junction. When acetylcholine cannot be released, the targeted muscle cannot contract as forcefully. Dynamic wrinkles — the lines created by repeated muscle movement — soften or disappear.
The difference with Xeomin is in its formulation. Xeomin is produced using a manufacturing process that removes the accessory (complexing) proteins that surround the botulinum toxin molecule in other products. The result is what Merz calls a "naked" toxin: pure botulinum toxin type A without the protein shell.
Whether this matters clinically is debated. The theoretical argument is that accessory proteins are unnecessary for the toxin's mechanism of action and may trigger an immune response in some patients, potentially leading to antibody formation and reduced treatment efficacy over time. There is no large-scale clinical trial proving that Xeomin has lower immunogenicity than Botox in aesthetic use, but the formulation difference is real and the theoretical rationale is sound.
FDA-approved cosmetic indications
Xeomin is FDA-approved for the temporary improvement in the appearance of:
- Moderate to severe glabellar lines (frown lines between the eyebrows, associated with corrugator and/or procerus muscle activity) — approved 2011
- Moderate to severe horizontal forehead lines (associated with frontalis muscle activity) — approved July 2024
- Moderate to severe lateral canthal lines (crow's feet, associated with orbicularis oculi muscle activity) — approved July 2024
Like all botulinum toxin products, Xeomin is widely used off-label for other areas including the masseter muscles (jaw slimming), platysma bands (neck), bunny lines (nose), lip flip, brow lift, and hyperhidrosis. Off-label use is standard in aesthetic medicine, but patients should understand that the FDA has not evaluated safety and efficacy for these applications.
Dosing: how Xeomin is measured and administered
Unit equivalency
Xeomin units are generally treated as clinically comparable to Botox units on a 1:1 basis in aesthetic practice. This means 20 units of Xeomin is expected to produce roughly similar effect as 20 units of Botox for the same treatment area.
However, the FDA label for all botulinum toxin products states that potency units are specific to each preparation and assay method and are not interchangeable. A provider experienced with both products will typically dose Xeomin the same as Botox for standard cosmetic areas, adjusting based on individual patient response over subsequent visits.
FDA-recommended cosmetic doses
The FDA-approved dosing for Xeomin's three cosmetic indications:
| Treatment area | Recommended dose | Injection points |
|---|---|---|
| Glabellar lines | 20 units total | 5 injections of 4 units each (2 per corrugator, 1 in procerus) |
| Forehead lines | 20 units total | Multiple injection sites across the frontalis |
| Lateral canthal lines (crow's feet) | 24 units total | 12 units per side, distributed across the orbicularis oculi |
A full upper-face treatment (all three areas) uses approximately 64 units total.
For therapeutic indications, dosing is higher: up to 120 units for cervical dystonia, up to 100 units for blepharospasm, and up to 400 units for upper limb spasticity.
How it is administered
Xeomin is supplied as a lyophilized powder in 50-unit, 100-unit, or 200-unit single-dose vials. The provider reconstitutes it with preservative-free 0.9% sodium chloride injection before use. Injections are intramuscular, delivered with a fine needle (typically 30 to 33 gauge). The procedure takes 10 to 20 minutes for cosmetic treatment.
No anesthesia is required, though some providers apply topical numbing cream or use ice for patient comfort. Discomfort is typically described as a brief pinching sensation.
Onset and duration
| Parameter | What to expect |
|---|---|
| Onset | Median onset occurs within 2 to 7 days after injection |
| Full effect | Typically visible by day 7 to 14 |
| Duration | 12 to 16 weeks (approximately 3 to 4 months) for most patients |
| Retreatment interval | No more frequently than every 12 weeks per FDA labeling |
The FDA-approved Xeomin prescribing information states that the median onset of treatment effect occurs within 2 to 7 days and the typical duration is up to 12 to 16 weeks. Some patients report that Xeomin may last slightly longer than Botox with repeated use, but head-to-head trials have generally found comparable duration between the two products when dosed at equivalent unit amounts.
Individual variation is substantial. Factors that affect how long Xeomin lasts include muscle mass (larger muscles metabolize toxin faster), treatment area (high-mobility areas like the mouth tend to wear off faster), dose (higher doses within the safe range may last longer), metabolism, and previous neurotoxin exposure.
How Xeomin compares to other neuromodulators
| Feature | Xeomin | Botox | Dysport |
|---|---|---|---|
| Generic name | IncobotulinumtoxinA | OnabotulinumtoxinA | AbobotulinumtoxinA |
| Manufacturer | Merz | AbbVie/Allergan | Ipsen/Galderma |
| Accessory proteins | No (naked toxin) | Yes | Yes |
| FDA cosmetic approvals | Glabella, forehead, crow's feet | Glabella, forehead, crow's feet, platysma bands | Glabella |
| Unit conversion | 1:1 with Botox | Reference | ~2.5 to 3:1 with Botox |
| Onset | 2 to 7 days | 3 to 5 days | 2 to 5 days |
| Duration | 3 to 4 months | 3 to 4 months | 3 to 4 months |
| Storage | Room temperature (before reconstitution) | Refrigerated | Refrigerated |
| Cost per unit | $8 to $18 | $10 to $20 | $4 to $8 |
For comparisons with Daxxify, Jeuveau, and Letybo, see our comparison articles: Daxxify vs Botox, Dysport vs Xeomin, and Letybo vs Botox, Dysport, and Xeomin.
Who Xeomin suits best
Good candidates
- First-time neuromodulator patients who want a product with a clean formulation and a long safety track record (FDA-approved since 2010 for therapeutic use, 2011 for cosmetic use)
- Patients who have developed reduced response to Botox over time and want to try a product without accessory proteins, based on the theoretical lower immunogenicity risk
- Patients seeking a product that does not require refrigeration during storage and shipping, which can reduce costs for the practice and may reduce the risk of product degradation
- Patients who want all three upper facial areas treated in one session with a single product that carries FDA approval for each area
- Patients who feel their current neurotoxin creates heaviness in the brow or lids, as some experienced injectors report that Xeomin tends to produce a lighter, more natural-feeling result — particularly valued by actors and patients who need to maintain full facial expressiveness
When another product may be more appropriate
- Patients who want the longest possible duration: Daxxify has shown median duration of up to 6 months in clinical trials, roughly double the standard 3-to-4-month duration of Xeomin and Botox. However, Daxxify's longer duration was demonstrated at a 40-unit dose for glabellar lines, which is double the 20-unit dose used for Xeomin and Botox in the same area.
- Patients who prefer a product with broader FDA cosmetic approvals: Botox Cosmetic is additionally FDA-approved for platysma bands (neck lines), which Xeomin is not.
- Patients whose provider has more experience with another product: Injector experience with a specific product matters more than the product itself for achieving natural-looking results.
Cost
Xeomin is typically priced comparably to or slightly below Botox:
| Measure | Xeomin | Botox |
|---|---|---|
| Cost per unit | $8 to $18 | $10 to $20 |
| Cost per 100-unit vial (wholesale) | ~$542 | ~$694 |
| Full upper face (64 units) | $500 to $1,150 | $640 to $1,280 |
| Glabellar lines only (20 units) | $160 to $360 | $200 to $400 |
These ranges reflect national averages. Actual cost varies by geography, provider credentials, and practice type. Xeomin is often priced 10 to 20% below Botox per unit, though the total out-of-pocket cost for equivalent treatment areas is often similar because the number of units used is the same.
Merz offers the Xeomin Rewards program, which can reduce costs for eligible patients. Botox offers a similar program (Allergan Rewards). Both programs change their terms periodically.
Risks and side effects
Common side effects
These are typically mild and self-limiting:
- Injection-site pain, redness, swelling, or bruising
- Headache (reported in clinical trials for glabellar lines)
- Temporary eyelid ptosis (drooping), which usually resolves within 2 to 4 weeks
- Brow asymmetry or heaviness
Serious risks
The Xeomin prescribing information carries the same boxed warning as all botulinum toxin products: the effects of the toxin may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection and can include generalized muscle weakness, double vision, blurred vision, drooping eyelids, loss of bladder control, hoarseness, change or loss of voice, difficulty speaking clearly, trouble swallowing, and breathing difficulties. These symptoms can be life-threatening.
The risk of distant spread is greatest in children treated for spasticity and is considered very rare in adults receiving cosmetic doses. The FDA-recommended maximum cumulative dose for Xeomin in any treatment session is 400 units for therapeutic indications. Cosmetic doses (20 to 64 units total) are well below this threshold.
Contraindications
Xeomin should not be used in patients with:
- Known hypersensitivity to any botulinum toxin product or to any component of the formulation
- Active infection at the proposed injection site(s)
- Pregnancy (no adequate studies in pregnant women; botulinum toxin should be used only if clearly needed)
Patients taking aminoglycoside antibiotics, cholinesterase inhibitors, or other agents that interfere with neuromuscular transmission should inform their provider, as these may potentiate the effect of the toxin.
Questions to ask your provider
- How many Xeomin treatments have you performed? Experience matters more than the product brand for achieving natural results.
- What dose do you plan to use for each area? If this is your first treatment, your provider may start conservatively and adjust at follow-up.
- Do you offer a two-week follow-up? This is standard practice to assess results and add more units if needed for symmetry.
- What is your protocol if I experience ptosis or asymmetry? An experienced provider can offer apraclonidine drops for ptosis and targeted touch-ups for asymmetry.
- Are you using genuine Xeomin? The FDA has issued warnings about counterfeit botulinum toxin products. Your provider should be able to show you the labeled vial.
Sources
- Merz Pharmaceuticals. "XEOMIN (incobotulinumtoxinA) Prescribing Information." Revised 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125360s097lbl.pdf
- Xeomin Aesthetic. "XEOMIN Prescribing Information and Medication Guide." https://www.xeominaesthetic.com/wp-content/uploads/2026/02/xeomin-pi-med-guide.pdf
- U.S. Food and Drug Administration. "XEOMIN — Drug Approval Package." https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125360lbl.pdf
- American Board of Cosmetic Surgery. "FDA Approves Xeomin for Comprehensive Facial Wrinkle Treatment." https://www.americanboardcosmeticsurgery.org/blog/fda-approves-xeomin-for-comprehensive-facial-wrinkle-treatment
- Drugs.com. "Xeomin vs Botox: How Do They Compare?" https://www.drugs.com/medical-answers/xeomin-botox-how-compare-3579643
- Drugs.com. "Xeomin (IncobotulinumtoxinA) FDA Approval History." https://www.drugs.com/history/xeomin.html
- Empire Medical Training. "Xeomin vs Botox: 2025 Comparison Guide for Wrinkle Treatments." https://www.empiremedicaltraining.com/blog/xeomin-vs-botox
- Aesthetic Training. "FDA-Approved Botulinum Toxins for Aesthetic Use Comparison." https://aesthetic-training.com/fda-approved-botulinum-toxins-for-aesthetic-use-comparison
- American Society of Plastic Surgeons. "Botulinum Toxin Type A: Average Cost." https://www.plasticsurgery.org/cosmetic-procedures/botulinum-toxin/cost
